MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications

Halifax, Nova Scotia, 21st of January, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional […]
Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test – A Potential Game Changer to Address Syphilis Health Crisis in Canada

Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) with the goal of getting it licensed in Canada. The new Multiplo® TP/nTP will provide a complete system which combines screening and confirmation in […]
Update on MedMira’s Regulatory Path in Canada and the USA

Halifax, Nova Scotia, 27 September, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious disease rapid tests. Currently the Company has two submissions filed with Health Canada and one submission with the US FDA. In addition, the Company […]
Update on MedMira’s Reveal® TP (Syphilis) Clinical Trials in Canada

Halifax, Nova Scotia, 14 March, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test. The Company has successfully started its clinical trials in Saskatchewan in early March 2023 and commences another trial in British Colombia by the […]
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trial underway in Canada. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark. Furthermore, the Company continues their work on […]
MedMira Provides a Pre-Annual General Meeting Update

Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development progress. This includes its COVID-19 and its infectious disease products with the latest pre-submission for MedMira’s HCV Rapid Test to the FDA. This update serves the purpose to inform […]